<![CDATA[Enfortumab Vedotin Combo Boosts MIBC Survival Outcomes in EV-304 Trial]]>
Findings from the phase 3 KEYNOTE-B15/EV-304 trial (NCT04700124) revealed significant improvements in event-free survival (EFS), overall survival (OS), and pathological complete responses (pCR) with perioperative enfortumab vedotin-ejfv (EV; Padcev) …